 NEW YORK--BUSINESS WIRE-- Revance--Bragar Eagel Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Revance Therapeutics, Inc. Revance or the Company NASDAQ: RVNC on behalf of Revance stockholders. Our investigation concerns whether Revance has violated the federal securities laws andor engaged in other unlawful business practices. Click here to participate in the action. On October 12, 2021, the U.S. Food and Drug Administration 